CONNECT WITH US
eCommerce

eCommerce

US FDA Approves Phase 2 Clinical Trial of Injectable PDGF for Under-Eye Hollows

Global Cosmetics News logo

Published on

Add as a preferred source on Google
US FDA Approves Phase 2 Clinical Trial of Injectable PDGF for Under-Eye Hollows

THE WHAT? The US Food and Drug Administration (FDA) has cleared Lynch Regenerative Medicine’s Investigational New Drug application for a Phase 2 clinical trial evaluating injectable recombinant human platelet-derived growth factor-BB (rhPDGF-BB) as a treatment for under-eye hollowing.

THE DETAILS The multicentre, randomised trial will assess the safety, tolerability and preliminary efficacy of injectable rhPDGF-BB in adults with infraorbital hollowing. Researchers will measure improvements in under-eye appearance over 12 weeks, alongside tissue quality, patient-reported outcomes and immunogenicity. Patient enrolment is expected to begin within weeks. Lynch Regenerative Medicine also markets ariessence pure PDGF+, a separate topical cosmetic product containing rhPDGF-BB and hyaluronic acid serum.

THE WHY? The development highlights growing interest in regenerative approaches to aesthetic treatments, particularly those targeting skin quality and tissue restoration. While the injectable formulation remains investigational, the trial could provide further clinical evidence for the use of growth factors in aesthetic medicine, a field increasingly connected to advanced skincare innovation.



Source link
Related Topics:eCommerce

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.